Predictive model for acute abdominal pain after transarterial chemoembolization for liver cancer

Table 2 Demographic, clinical, laboratory, and procedural variables of patients (2)

Variable	n	%
Sex
Female	81	13.9
Male	501	86.1
Disease type
No surgery	371	63.7
Recurrence after surgery	211	36.3
TACE history	333	57.2
History of abdominal pain after TACE	73	12.5
Pathological properties
HCC	280	48.1
ICC	13	2.2
Unknown	265	45.5
Other	24	4.1
Tumor size
≤ 5 cm	334	57.4
> 5 cm	248	42.6
Number of tumors
≤ 2 (non-multiple)	197	33.8
> 2 (multiple)	385	66.2
Invasion of blood vessels	176	30.2
Blank microsphere	138	23.7
PVA particles	63	10.8
Method of TACE
Traditional TACE	336	57.7
DEB-TACE	246	42.3
Prophylactic analgesics
Tenay	74	12.7
Kaffin	112	19.2
Dezocine	252	43.3
Pentam	29	5
None	58	10
Two painkillers	57	9.8
Pain after TACE
No pain/mild pain	485	83.3
Moderate pain/severe pain	97	16.7

TACE: Transarterial hepatic chemoembolization; DEB-TACE: Transarterial chemoembolization with drug-eluting beads; HCC: Hepatocellular carcinoma; ICC: Intrahepatic cholangiocarcinoma; PVA: Polyvinyl alcohol.